Biocon Limited
Climate Impact & Sustainability Data (2021, 2022-04 to 2023-03, 2023-04 to 2024-03, 2024, Q2 FY23)
Reporting Period: 2021
Environmental Metrics
ESG Focus Areas
- Patient Equity
- People Equity
- Social Equity
- Environmental Equity
- Stakeholder Equity
Environmental Achievements
- 18% reduction in absolute Scope 1 and Scope 2 emissions (vs FY20 baseline)
- 53% of electricity from green power
- 100% of wastewater recycled and reused
- ~5,500 tonnes of high-calorific waste sent for reuse as fuel
- 400,000 liters of incremental water savings per day achieved through installation of a new ZLD effluent treatment plant
- 17,092 tCO2 reduction from switchover to natural gas from furnace oil
Social Achievements
- ~61,000 patient visits at Biocon Foundation-run eLAJ smart clinics
- ~2,200 people screened for oral cancer using mHealth app
- 700+ biotech graduates upskilled at Biocon Academy
- Repurposed Itolizumab for treating COVID-19 patients (27,000+ lives impacted)
- 185,000 RT-PCR Tests for COVID-19 conducted
- 3.1 million patients reached globally through biosimilars
- 96.8 million in CSR spending
Governance Achievements
- Robust governance policies (Code of Conduct, Whistle-blower policy, etc.)
- Five Board committees
- Strong Quality Management System aligned with GxP
- Appointed a team of 120 Local Ethics Officers (LEOs) to ensure compliance to the Code of Conduct
- Zero tolerance for child labor
Climate Goals & Targets
- 50:50 gender ratio by 2030
Environmental Challenges
- Inequity in global healthcare access
- COVID-19 pandemic impact
Mitigation Strategies
- Partnerships with UNAIDS, CHAI, etc.
- ‘Mission 10 cents’ insulin initiative
- Repurposing Itolizumab for COVID-19 treatment
- Proactive COVID-19 safety measures for employees
Supply Chain Management
Responsible Procurement
- Local sourcing
- Responsible raw material sourcing
Climate-Related Risks & Opportunities
Reporting Standards
Frameworks Used: GRI
Certifications: ISO 14001:2015 & ISO 45001:2018
Sustainable Products & Innovation
- Reusable insulin pens
Awards & Recognition
- ISPE Facility of the Year Award (Honorable Mention)
- Avtar Women’s lists of ‘Best Companies for Mothers’ and ‘Most Inclusive Companies’
- UN Women recognition for promoting gender diversity
- DivHERsity Awards for ‘Most Innovative Practices’
Reporting Period: 2022-04 to 2023-03
Environmental Metrics
ESG Focus Areas
- Climate Change
- Diversity & Inclusion
- Access to Medicines
- Sustainable Operations
- Responsible Supply Chain
Environmental Achievements
- Increased green power usage to 60.4% of total power requirement.
- Reduced CO2 emissions by 120,950 tons through renewable energy and fuel switching.
- Commissioned India’s largest biomass boiler for process steam, reducing CO2 emissions.
- Achieved 75% renewable energy at major sites in Q4 FY23.
Social Achievements
- Launched several employee well-being programs.
- Secured USD 1.2 billion Sustainability Linked Loan (SLL) tied to ESG targets.
Governance Achievements
- Established robust sustainability governance framework and strategy.
- Board-level oversight of climate-related issues.
- ESG linked performance in employee scorecards (5% weightage).
Climate Goals & Targets
- Net-zero emissions
- Achieve 90% renewable energy for Bengaluru sites by 2025.
- Reduce Scope 1 and 2 emissions by 20% by 2032.
- Reduce Scope 3 emissions by 10% by 2032.
- Reduce water consumption.
- Increase renewable energy to 90% at Bengaluru sites by 2024.
Environmental Challenges
- Water stress impacting operations.
- Risk of flooding at manufacturing sites.
- Reputational risks from stakeholder concerns on climate action.
- Unsuccessful investment in new technologies.
- Enhanced emissions-reporting obligations.
- Heat stress impacting employee health and operations.
Mitigation Strategies
- Implementing water conservation measures (recycling, reuse, storage).
- Developing business continuity plans for extreme weather events.
- Transparent reporting on climate strategy and measures.
- Robust quality and manufacturing systems for low-carbon transitions.
- Integrating climate risks into enterprise risk management.
- Employee benefits and wellness programs, engineering controls.
Supply Chain Management
Supplier Audits: 28 GMP audits in FY23
Responsible Procurement
- Supplier Code of Conduct
- ESG criteria for vendor evaluation
- Sustainability requirements
Climate-Related Risks & Opportunities
Physical Risks
- Water stress
- Flooding
- Heat stress
Transition Risks
- Technological change
- Market shifts
- Regulatory changes
Opportunities
- Resource efficiency
- Market demand for low-carbon products
- Renewable energy
Reporting Standards
Frameworks Used: TCFD, GRI, BRSR, UNGC
Third-party Assurance: DNV
UN Sustainable Development Goals
- Goal 7 (Affordable and Clean Energy)
- Goal 13 (Climate Action)
Initiatives contribute to these goals through renewable energy adoption, emissions reduction, and community projects.
Sustainable Products & Innovation
- Low-carbon APIs identified through LCA
Awards & Recognition
- S&P Global Sustainability Yearbook
- BW Businessworld Annual Rating
- Golden Peacock Award for Sustainability
- UNWEP India award
- Best Sustainability Practices in Procurement award
Reporting Period: 2023-04 to 2024-03
Environmental Metrics
ESG Focus Areas
- Product quality
- Research and Development
- Access & affordability
- Environmental performance
- Future ready workplace
- Digitization
- Supply chain sustainability
- Community engagement
- Inclusion and diversity
- Governance
- Ethical sales and marketing
- Climate
Environmental Achievements
- Recycled 78% of water (up from 60% the previous year)
- Recycled 83% of waste generated
- 58% of total power consumed sourced from renewable sources
- 18,765 tCO2e GHG emissions (Scope 1 and Scope 2) offset
- 155,414 metric tons of CO2 emissions avoided due to energy saving initiatives
- 100% of wastewater generated (India Operations) recycled and reused
Social Achievements
- Achieved 17.6% women in workforce at Biocon Limited
- Biocon Biologics reached out to 1,100+ patients through donation programs in low- and middle-income countries
- Donation of approximately 12,500 insulin glargine injection pens and 1,000 glargine vials
- Collaboration with Action4Diabetes (A4D) to supply insulin at subsidized costs
Governance Achievements
- Implemented an anti-corruption and anti-bribery policy
- Established ‘Corporate Social Responsibility and Environmental, Social and Governance Committee’
Climate Goals & Targets
- 25% reduction in Scope 1 and Scope 2 emissions by FY29 from baseline year FY20
- 25% freshwater consumption reduction by FY29 from baseline year FY23
- 100% circular waste by FY29 from baseline year FY23, includes zero waste to landfill by FY29
- To plant 15,000 trees by FY29
- At least 20% women in the workforce by 2025 at Biocon Limited
Environmental Challenges
- Product quality risks (recalls, safety, regulatory compliance)
- Environmental performance risks (regulatory compliance, climate change)
- Future ready workplace risks (safe workplace, talent retention)
- Supply chain sustainability risks (disruptions, dependencies)
- Governance risks (ethics, compliance)
Mitigation Strategies
- Stringent quality control measures, automated processes, digital initiatives, improved quality culture, continuous training
- Sustainable practices (renewable energy, water usage, waste management), climate risk considerations in business strategy
- Robust safety procedures, continuous improvement initiatives, employee well-being programs, talent mobility, succession planning
- Integrated approach, cost-effective logistics, supplier audits, Supplier Code of Conduct, alternative vendors, inventory management
- Global best practices in corporate governance and risk management, independent compliance tracking
Supply Chain Management
Supplier Audits: 11 critical vendors/suppliers assessed at BL, 127 critical vendors assessed at BBL
Responsible Procurement
- Supplier Code of Conduct
- Biocon Biologics’ Business Partner Code of Conduct
- Periodic audits on business sustainability parameters
Climate-Related Risks & Opportunities
Physical Risks
- Extreme weather events
Transition Risks
- Regulatory pressures
Opportunities
- Resource conservation
- Energy efficiency
Reporting Standards
Frameworks Used: GRI Standards 2021, UNGC, S&P Global Dow Jones Sustainability Indices (DJSI), BRSR (Core) framework by SEBI, AA1000AS v3
Certifications: ISO 14001, ISO 45001, ISO 27001:2013, GMP
Third-party Assurance: Emergent Ventures India Pvt. Ltd.
Awards & Recognition
- S&P Global’s Sustainability Yearbook for 2024
- EcoVadis Silver Medal
Reporting Period: 2024
Environmental Metrics
ESG Focus Areas
- Environment
- Social
- Governance
Environmental Achievements
- Reduced energy usage by 3%
- Achieved 82% power from renewable sources
- Saved 78,225 Kiloliters of water through recycling and reuse
- Recycled 96% of total hazardous and non-hazardous waste
- Achieved zero waste to landfill at all facilities
Social Achievements
- Contributed to funding of IISc Post Graduate medical school and hospital
- Contributed to the new Bangalore metro
- Extended Synquizitive science quiz to 7,500 students
- Revamped employee induction process
- Achieved 88% employee engagement score
Governance Achievements
- Committed to Science-Based Targets (SBTi) for greenhouse gas emissions reduction
- US FDA approval for API manufacturing facility in Mangalore
- Received ISO: 50001 certification for energy conservation
- Recognized as one of ‘India’s Best Managed Companies’ by Deloitte India
Climate Goals & Targets
- 67% of suppliers representing Scope 3 emissions to commit to SBTi targets
- Reduce Scope 1 and 2 greenhouse gas emissions by 50% by 2033
Environmental Challenges
- Challenging financing environment in US biotech impacting Discovery Services revenue and margins
- Price sensitivity from clients and price aggression from competitors
- Slowdown in outsourcing due to normalization of biotechnology funding levels
Mitigation Strategies
- Expanded operations in Hyderabad with integrated chemistry and biology services
- Commissioned automated compound management facility
- Acquired new capabilities such as oligonucleotide synthesis
- Focus on digitization and automation to drive efficiency
- Leveraging customer-centric mindset to build partnerships
- Investment in robust leadership, exceptional talent and cutting-edge technology
Supply Chain Management
Responsible Procurement
- ESG assessment of critical suppliers
- Upskilling sessions for suppliers
- Commitment to decarbonization aligned with SBTi goals
Climate-Related Risks & Opportunities
Reporting Standards
Frameworks Used: SBTi
Certifications: ISO 45001, ISO 50001
Awards & Recognition
- India’s Best Managed Companies (Deloitte)
- Best Overall Sustainable Performance Award
- Silver Award in Environmental Excellence
- Best Energy Efficient Case Study (CII)
- Supply Chain Champion in Pharmaceutical Sector (ISCM)
Reporting Period: Q2 FY23
Environmental Metrics
ESG Focus Areas
- Environment
- Social
- Governance
Environmental Achievements
- 58% electricity came from green power
- 100% waste water recycled & reused
- 118K tCO2 GHG offset
Social Achievements
- Top 5 among global pharma & biotech employer since 2012
- Published Human Rights Policy
- Recognized by UN Women for efforts to promote diversity
- Rs. 11 Crore in CSR Spend
- 13% increase in women in workforce
- 5.3M patients reached through biosimilars
Governance Achievements
- Board Committees, policies for global governance
- Published 1st Tax Policy & Transparency Report, Supplier Code of Conduct
- Published 1st GRI aligned ESG & BRSR Report for FY22
Climate Goals & Targets
Supply Chain Management
Responsible Procurement
- Supplier Code of Conduct
Climate-Related Risks & Opportunities
Reporting Standards
Frameworks Used: GRI
UN Sustainable Development Goals
- UN Sustainable Development Goals (SDGs)
Biocon has drawn up a manifesto to deliver on its commitment to universal healthcare.